Related Experiment Video
Updated: Jun 21, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command
Mark S Freedman1, Bruce Cohen, Suhayl Dhib-Jalbut
1University of Ottawa, Smyth Rd., Ottawa, ON, Canada K1H 8L6. mfreedman@ottawahospital.on.ca
Objective:
The therapies available today for multiple sclerosis (MS) reduce but do not fully control disease activity. The objective of this article is to review the definitions of and treatments for suboptimally controlled MS and highlight the challenges faced by clinicians to increase awareness of recognizing and managing patients with suboptimally controlled MS.
Methods:
Published literature describing treatment failure, treatment optimization paradigms or algorithms, clinical studies of therapies in patients with suboptimally controlled MS, or case reports of management of patients with suboptimally controlled MS were identified from searches of EMBASE and MEDLINE. This was supplemented with case reports and discussions from an expert panel meeting of MS specialists focused on the diagnosis and treatment of suboptimally controlled MS.
Results:
Several groups have created recommendations for evaluating suboptimal response to disease-modifying drugs (DMDs) in MS. Currently no robust evidence-based data exist to guide treatment decisions in patients who have suboptimal response to a particular therapy. In the absence of data, several treatment paradigms for suboptimally controlled MS have been proposed using a step therapy or platform therapy approach. Therapy modifications require consideration of disease- and patient-specific factors while accounting for the risk-benefit profile of the agent(s). Unapproved drugs and combination therapies should be reserved as agents of last resort because of the experimental nature of these treatments.
Conclusions:
In the absence of evidence-based data, identifying and treating MS patients with suboptimal response to the available platform therapies remains challenging. Developing algorithms able to quantify breakthrough disease activity and suboptimal response to DMDs in individual MS patients remains an important target for the MS community. Consideration should be given for all reasons why a particular DMD may not be working for a given patient and for the use of an individualized step therapy.
Insights
Managing multiple sclerosis (MS) that is suboptimally controlled remains challenging due to a lack of evidence-based treatment guidelines. Individualized approaches are needed to optimize therapies for patients with breakthrough disease activity.
Area of Science:
- Neurology
- Immunology
Background:
- Current multiple sclerosis (MS) therapies offer disease reduction but not complete control.
- Suboptimally controlled MS presents significant challenges in clinical management.
Purpose of the Study:
- To review definitions and treatments for suboptimally controlled MS.
- To increase clinician awareness in recognizing and managing these patients.
Main Methods:
- Literature search of EMBASE and MEDLINE for treatment failure and optimization studies.
- Inclusion of expert panel discussions on diagnosing and treating suboptimally controlled MS.
Main Results:
- Recommendations exist for evaluating suboptimal response to disease-modifying drugs (DMDs).
- Limited evidence-based data guide treatment decisions for suboptimal response.
- Proposed treatment paradigms include step therapy and platform therapy approaches.
Conclusions:
- Identifying and treating MS with suboptimal response to platform therapies is challenging without robust data.
- Developing algorithms to quantify breakthrough disease activity is a key goal.
- Individualized step therapy and consideration of all factors influencing DMD efficacy are crucial.
Related Concept Videos
Multiple Sclerosis l: Introduction
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview

